<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853983</url>
  </required_header>
  <id_info>
    <org_study_id>D8180C00013</org_study_id>
    <nct_id>NCT00853983</nct_id>
  </id_info>
  <brief_title>Phase I Study to Assess Absorption, Metabolism &amp; Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers</brief_title>
  <official_title>An Open-Label, Phase I Study to Assess Absorption, Metabolism and Excretion of a Single Oral Dose of [14C]AZD0530 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to show how the body absorbs, metabolises and excretes the drug
      [14C]AZD0530. As for all clinical trials, safety and tolerability of the drug will be
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterise the absorption, metabolism and excretion of a single oral dose of 400mg [14C]AZD0530</measure>
    <time_frame>Multiple PK, Urine and faeces samples taken between predose to 240 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety profile by assessment of adverse events, physical examination, pulse, blood pressure, clinical chemistry, haematology, urinalysis &amp; ECG</measure>
    <time_frame>From time of consent to last visit</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] AZD0530</intervention_name>
    <description>Solution, Oral, once</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Regular Daily Bowel movements

          -  Veins suitable for cannulation or repeated venepuncture

        Exclusion Criteria:

          -  Presence of any clinically significant illness

          -  Abnormal vital signs

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism or excretion of
             drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj Chetty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca, Clinical Pharamcology Unit, Alderley Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Stuart, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca, Parklands, Alderley Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alderley Park</city>
        <state>Cheshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <last_update_submitted>May 20, 2009</last_update_submitted>
  <last_update_submitted_qc>May 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mary Stuart, MD, Medical Science Director, Emerging Product Team 1, Oncology</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <keyword>ADME</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saracatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

